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Dermatomyositis is well known to be associated with several types of malignancy and patients with dermatomyositis have higher
rates of mortalityfrom cancer. Although rare in Japan, head and neck cancer, especially nasopharyngeal cancer, is thepredominant
type of cancer associated with dermatomyositis in several areas in Asia, including Hong Kong and Singapore. Here we report two
cases of head and neck cancer with dermatomyositis as well as a literature review. Both cases were treated with chemotherapy and
radiotherapy. Although the patients were immunosuppressed due to dermatomyositis treatment, no grade 3 or 4 adverse events
occurred.
1.Introduction
Dermatomyositis is a connective tissue disease with charac-
teristic cutaneous manifestations and it is well known that
dermatomyositis is associated with various types of cancer.
The ﬁrst suggestion that dermatomyositis was associated
with cancer was made by Sterz in 1916 [1]a n dn u m e r o u s
cases have since been reported. In this paper, two cases of
patients with head and neck cancer along with dermato-
myositis are reported.
2.CaseReports
2.1. Case 1. A 79-year-old man was admitted to our hospital
with nasal bleeding and left cheek swelling suggestive of
maxillary sinus carcinoma. A solid mass with aggressive
bone destruction was detected in the left maxillary sinus
on contrast-enhanced computed tomography images. For
1 month, the patient had noticed a systemic rash, the
typical heliotrope coloration of the upper eyelids, Gottron’s
sign on the dorsal surface of his proximal interphalangeal
joints, erythematous areas at the bases of the ﬁngernails
(Figure 1),dysphagia,andproximalmuscleweaknessofboth
extremities, but he and his family did not think that the
symptoms were serious. On the second day of hospital-
ization, his respiratory dysfunction progressed rapidly. His
chest X-ray was normal and initial investigations revealed
a normal complete blood count and negative antinuclear
antibody and anti Jo-1 antibody levels. However, there
were several abnormal laboratory test results, including
increases in aspartate aminotransferase (AST) (451IU/L;
normal range, 8–33IU/L), alanine aminotransferase (ALT)
(90IU/L; normal range, 3–30IU/L), creatine kinase (CK)
(8,800IU/L; normal range, 15–166IU/L), lactate dehydro-
genase (LDH) (973IU/L; normal range, 118–226IU/L), and
aldolase (ALD) (23.3IU/L; normal range, 0.60–7.60IU/L).
His clinical symptoms fulﬁlled the criteria for the diagnosis
of dermatomyositis and it was thought that his respiratory
dysfunction was caused by acute interstitial pneumonia
associated with dermatomyositis. Therefore, the patient was
immediately treated with 40mg/day prednisolone, as well as
intravenous cyclophosphamide pulse therapy. The patient’s
clinical course is shown in Figure 2. His dyspnea and dys-
phagia recovered rapidly after the second cyclophosphamide
pulse treatment. Gradually, the patient’s other symptoms
improved and tapering of the prednisolone treatment was
begun. After the patient’s general condition had stabilized,
investigation of the patient’s maxillary sinus tumor was2 International Journal of Otolaryngology
Figure 1: Gottron’s sing on the dorsal surface of the proximal interphalangeal joint. Erythematous areas at the bases of the ﬁngernails are
seen.
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Figure 2: Case 1: Clinical Course. Treatment and serum CK levels are shown. CP: cyclophosphamide.
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Figure 3: Case 2: Clinical Course. Treatment and serum CK levels are shown.
begun. A transgingival biopsy specimen taken from the
maxillary sinus showed an undiﬀerentiated carcinoma. The
clinical TNM stage was T4N0M0. The patient was ﬁrst
treatedwithneoadjuvantchemotherapyconsistingofa5-day
continuous infusion of 5-ﬂuorouracil (700mg/day) with an
intra-arterial injection of cisplatin (70mg/body) through the
left superﬁcial temporal artery. One month later, the patient
underwent partial maxillectomy under general anesthesia;
the prednisolone dose was only 10mg/day at that time.
Then, radiotherapy of 50Gy by Linac was administered to
the primary site and the upper neck. The skin exposed to
the radiation developed mild moist desquamation, but noInternational Journal of Otolaryngology 3
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Figure 4: PET-CT. (a) Pre-treatment. Intense FDG uptake is detected in the left cervical region and the nasopharynx. Mild FDG uptake
is detected in the muscles of the entire body, especially the upper extremities. (b) Post-treatment. FDG uptake with residual tumor is not
detected. FDG uptake in the muscles is improved compared to pre-treatment.
exaggerated radiation reactions were noted. No grade 3 or 4
adverse events occurred during treatment. One month after
the end of radiotherapy, computed tomography scan and
ﬁberscopic examination revealed no residual cancer in the
maxillary sinus.
2.2. Case 2. A 42-year-old man was admitted to our hospital
for nasopharyngeal carcinoma. The biopsy specimen from
the nasopharynx disclosed nonkeratinizing cell carcinoma.
The clinical TNM stage was T1N2bM0. On admission, the
patient reported general fatigue and dysphagia. A diagnosis
of dermatomyositis was made on the basis of a systemic
rash, characteristic muscle weakness, compatible skin his-
tological result, and increased levels of CK (1490IU/L),
AST (108IU/L), ALT (74IU/L), LDH (447IU/L), and myo-
globin (488.7µg/L; normal range, 16.3–96.2µg/L). Antinu-
clear antibody and antiJo-1 antibody levels were negative.
The nasopharyngeal carcinoma was treated ﬁrst, and the
dermatomyositiswastreatedsecond,becauseitwasnecessary
toavoidtheimmunosuppressioninducedbyprednisolonein
case of neck dissections if there were residual tumors after
chemoradiotherapy. On the second day of hospitalization,
chemoradiotherapy was started. Radiotherapy of 66Gy by
Linac was administered to an area extending from the
nasopharynx to the lower neck at a rate of 2Gy/day.
Simultaneously, weekly chemotherapy was initiated through
an intravenous drip of 30mg of nedaplatin and 20mg of
docetaxel repeated ﬁve times. The tumor size decreased4 International Journal of Otolaryngology
rapidly within the ﬁrst 2 weeks. However, the patient’s
dermatomyositis symptoms progressed; in particular, the
CK level increased from 1490IU/L to 2893IU/L. Therefore,
prednisolone at 60mg per day was started. Two weeks
later, the CK level decreased spontaneously to 332IU/L.
The patient’s clinical course is shown in Figure 3.F i v e
months after treatment was ﬁnished, positron emission
tomography/computed tomography (PET-CT) showed no
residual tumor so no neck dissections were carried out. Pre-
and posttreatment PET-CT scans are shown in Figure 4.
3. Discussion
Dermatomyositis is well known to be associated with cancer;
various studies have reported its incidence ranging from
7% to 34% [2]. The carcinoma types vary in each country.
Hill et al. reported that ovarian, lung, gastric, colorectal,
and pancreatic cancers were most strongly associated with
dermatomyositis in several northern European countries [3],
whereas Wong reported that nasopharyngeal carcinoma was
as high as 75% in Hong Kong [4]a n dA n ge ta l .r e p o r t e d
a rate of 50% in Singapore [5]. On the other hand, in
Japan, gastric, lung, breast, and ovarian cancers were most
associated with dermatomyositis (in order of frequency)
[6].
Diagnosticcriteriafordermatomyositis[7]areasfollows:
(1) progressive symmetric muscle weakness of the inferior
and superior extremity girdle with or without dysphagia
and with respiratory muscle involvement; (2) muscle biopsy
conﬁrming myositis; (3) increase in muscle enzyme serum
levels; (4) electromyography abnormality indicating primary
muscle damage; (5) characteristic skin lesions.
T h ep r e s e n c eo fs y m p t o m s1 ,3 ,a n d4i nC a s e1
conﬁrmedthediagnosisofdermatomyositisandthepresence
of symptoms 1, 2, 3, and 5 in Case 2 conﬁrmed the
diagnosis of dermatomyositis. Anti- Jo-1 antibody has a
high diagnostic speciﬁcity, but its positive rate is only
30% of cases. Anti-Jo-1 level were negative in these two
cases. Characteristically, both patients reported dysphagia
as one of their ﬁrst symptoms and the diagnoses of cancer
and dermatomyositis were made almost simultaneously. In
general, the risk of cancer is highest within the ﬁrst year
following diagnosis of dermatomyositis [3]. This makes the
diagnosis and treatment of dermatomyositis diﬃcult.
Dermatomyositis associated with cancer is generally
more resistant to corticosteroid and cytotoxic therapies than
idiopathic myositis. Dermatomyositis activity reﬂects the
state of cancer and some reports have described improve-
ment of dermatomyositis without immunosuppressive drugs
after the resection of the cancers [8, 9]. Eﬀective antitumor
treatment may be accompanied by regression of the inﬂam-
mation and yet it may result in progression in the stage of
cancer [10].
In Case 1, it was apparent that the patient was experienc-
ing acute dermatomyositis and acute interstitial pneumonia,
which could be fatal. Therefore, treatment of the dermato-
myositis with immunosuppressive drugs was given priority.
In Case 2, multiple cervical lymphadenopathy was advanced,
so it was necessary to avoid the immunosuppression induced
by prednisolone in case of neck dissections if there were
residual tumors after chemoradiotherapy. However, the
patient’s dermatomyositis symptoms progressed and oral
prednisolone was started. Fortunately, complete remission
was achieved at the end of chemoradiotherapy. If there had
been residual tumor in the cervical region, surgery would
not have been possible until the prednisolone dose had been
tapered suﬃciently and the opportunity to operate may have
been missed.
In both cases, radiotherapy was used to treat the head
and neck cancer because these two types of cancer have very
good sensitivity to radiation. Teo et al. reported that acute
conﬂuent mucositis necessitating interruption of radiother-
apy occurred in 8 of 9 nasopharyngeal carcinoma patients
with dermatomyositis, and 2 of 9 experienced chronic
radiation skin necrosis [11]. In addition, Hareyama et al.
reported that two patients with nasopharyngeal carcinoma
and dermatomyositis developed a severe skin reaction that
resultedinadeepneckabscessafterchemoradiotherapy[12].
Therefore, it is important to pay careful attention to skin and
mucous reactions secondary to radiotherapy with or without
chemotherapy.
In Case 2, concurrent chemoradiotherapy with nedaplat-
in and docetaxel was selected. Nedaplatin is easy to give in
complicated cases because it improves renal dysfunction and
does not need as much hydration as cisplatin. In addition,
docetaxel does not induce strong skin and mucous damage
compared to 5-ﬂuorouracil or S-1. In both cases, no grade
3 or 4 adverse skin events occurred. Therefore, these two
drug combinations appear to be good chemoradiotherapy
regimens [13, 14].
In the present cases, the autoimmune mechanism that
induced dermatomyositis was not clear and the absolute
number of cancer cases with dermatomyositis is small, so
further studies would be needed to establish the treatment.
4. Conclusion
We experienced two cases of head and neck cancer with
dermatomyositis. Both cases were treated with chemora-
diotherapy and complete remissions were achieved without
grade 3 or 4 adverse events. In general, it is important to
pay careful attention to skin and mucous reactions because
sometimes treatments induce severe complications such as a
deep neck abscess.
In the present cases, the autoimmune mechanism that
induced dermatomyositis was not clear and the absolute
number of cancer cases with dermatomyositis is small, so
further studies would be needed to establish the treatment.
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